1. BrECADD resulted in significantly lower treatment-related morbidity than eBEACOPP. 2. Progression-free survival at 48 months was significantly greater in ...
Click here to read this study in JAMA
1. In this randomized controlled trial, among the 121 patients with Duchenne muscular dystrophy (DMD) randomly assigned to a treatment ...
1. A combination of androgen deprivation therapy, docetaxel, and abiraterone (“triplet therapy”) had the best overall survival and progression-free survival ...
1. For the treatment of ANCA-associated vasculitis, avacopan was non-inferior to prednisone taper for the number of remissions at week ...
1. The addition of tocilizumab, a monoclonal antibody against interleukin-6 (IL-6), to a glucocorticoid taper sustained remission in patients with ...
